Iran has condemned US on killing our 3 Indian seafarers near Oman coast
Modi and his Bhakts call Israel and Netanyahu as friend, but they have not condemned US Navy killings of our Indian sailors but Iran did
This shows who is our real & fake friend
To all NRI Bhakts living in USA:
USA bombed 3 ships carrying Indian nationals & killed 3 Indians.
You danced when Modi came to America, you supported & voted Trump. Would you now dare to ask Trump why the USA did that?
Or Dollars are more important to you than India?
क्या आदित्य शर्मा की जान की कीमत कुछ भी नहीं है,
अगर यही काम पाकिस्तान ने किया होता तो अब तक एयरस्ट्राइक हो चुकी होती।
लेकिन अमेरिका ने किया है, तो जाने दो।
वो दोस्त है साब का।
#SpecialSituation#Indoborax Promoter change
From capital misallocation to prudent deployment, a tale captured in two images
Image 1: Cash generated in the business used for buying a residential property worth 42 crores instead of growing the business or returning the cash to shareholders while company had 70 cr Mcap
There are credible allegations made against Donald Trump that he mutilated a child’s nipples while raping her.
Allegations so serious, his inner circle had to meet in the Situation Room to discuss them.
I mean, how the fuck isn’t this the biggest scandal in the world right now?
😱😱😱 And just like that, it’s completely VANISHED from the media.
A sitting congressman, Ted Lieu, said on the record the Epstein files are being blocked because they show Trump raped and threatened to kill children.
Lets make this viral again 👇
#Acutaas#Acutaaschemicals
Acutaas Chemicals — The Flow Chemistry Patent Nobody Is Talking About
Most Indian chemical stocks compete on cost. Acutaas competes on who can even copy them.
One patent. Two industries. Zero substitutes.
Flow chemistry — the moat that serves both Big Pharma and the EV+Semiconductor revolution 🧵👇
What They Do (Business Verticals)
🔵 Pharma Intermediates — 610+ complex molecules for global drug makers
🔵 CDMO — Exclusive chemist for innovators like Fermion (Bayer's cancer drug Darolutamide)
🔵 EV + Semicon — First outside China to make EV electrolyte additives; India's only semiconductor photoresist maker
🔵 Specialty Chemicals — Parabens, salicylic acid, niche consumer materials
The pivot: from generic pharma supplier → deep-tech critical infrastructure.
The Real Moat: Flow Chemistry
Here's what most miss.
Acutaas doesn't just make chemicals. They make them via proprietary continuous flow chemistry processes that competitors simply cannot replicate.
Production-side moat:→ Multi-stage synthesis requires ₹150-200Cr+ capex + 4 years for regulatory clearance → 90%+ of intermediates made fully in-house → USFDA + PMDA approvals are non-transferable — new entrant = full re-audit
Demand-side customer stickiness:→ Their molecules get written INTO client drug patent filings → Switching supplier = $1-3M refiling + 2-3 years of comparative stability testing → Customer retention: 90-95% within CDMO/innovator contracts
Barriers to entry:→ You need the chemistry and the compliance and the regulatory trust — all simultaneously → In FY24, unorganized generic players were wiped out by Chinese dumping. Acutaas survived because they were already unreplicable.
This isn't a patent on a product. It's a patent on the process. You can't reverse-engineer a process you can't observe.
Tweet 4 — Financial Projection + Asymmetric Bet
Numbers back the thesis:
OPM went from 11.2% in FY24 → 42.4% in Q4FY26 as the mix shifted.
The asymmetric bet? Semiconductor photoresists.
Today Acutaas is India's sole manufacturer. Global market = $4.8B → $7.1B by 2030. Their target: 5% global share + 60% domestic share.
The capex is already deployed. The validation cycles are running. If even 1-2 Indian fabs (backed by India Semiconductor Mission) lock them in — the revenue step-change is non-linear.
PAT CAGR guided at ~38% through FY28. At 73x trailing P/E, it's not cheap — but at 40x forward FY28 earnings, it's a different conversation.
FCF is currently negative (-₹12 Cr) — that's the CapEx phase. It flips positive post-FY26. Watch that inflection.
Closing
Acutaas is rare: a company where the supply chain IS the product.
Promoters hold ~40%, zero pledge. Debt-free. ROCE at 31.6%.
The flow chemistry patents don't just protect margins — they determine whether customers can even leave.
[Not investment advice, DYOR]
Jet-powered #Drone is going to be a game changer in future warfare
It enables 500-1000 kmph speed vs 200-300 kmph
Reduced radar visibility combined with high speed makes it difficult to intercept
One Indian company will be big beneficiary of this.
TCS wants to hire an AI ML engineer with 5-7 years of experience, and the salary they are offering is 50,000-1.25L per annum.
I need whatever they’re smoking in there.